21 Jin him- a four-year 8 10000000-10 100 million marketing Apocalypse.docVIP

 PAGE \* MERGEFORMAT 24 21 Jin him: a four-year 810 100 million marketing Apocalypse 21 Jin He, the domestic first class multi-dimensional element of OTC drugs available in 1984, painstakingly built over 10 years, sales had not been Guoyi, in 2001, dropped to 80 million more. 21 Jin his back, is one of the earliest of the four Western pharmaceutical companies - Hangzhou Minsheng Pharmaceutical, a country with 77-year-old and famous enterprises. In November 2001, in our fully involved, the people’s livelihood and pharmaceutical decision-makers began a 21 Jin his new mode of operation. One year after the end of 2002, Minsheng Pharmaceutical Marketing Manager Chen Fei came good news: the statistics came out, full-year sales reached 150 million, an increase of 80%! And then less than 30 million advertising investment. 2003 1 to 8 months, 8 months, sales increased by 20 million bottles per month rate rose to August sales have been completed more than 3 million! By the end of 2003, achieving sales of 540 million. In 2004, the city of 8 million in consumer sales. In 2005, the target sales of 10 billion, based on current sales trend is entirely possible to achieve this goal. It is worth mentioning is: different from the HaYao mode, 21 Jin his success, instead of relying on traditional advertising carpet bombing, but rather in ensuring the full profit on the basis of the effectiveness of the use of Chinese characteristics, integrating marketing practices, in the shortest time Within the biggest victory won steadily. After all, not every business has a huge financial strength; after all, profit is a fundamental existence of the business; after all, more than one road leading to Rome. In advocating major investment in big-budget Chinese market, 21 Jin he had his own practice proved that: do not need to withstand the enormous risks and financial pressures can also risen rapidly, and in the short term profit. Recalling the 21 Jin his four operations, we